v3 Template
E

ExeVir Bio

Biotechnology / Healthcare ~460 employees
Founded
--
Employees (Est.)
~460
23 leaders known
Total Funding
$1.6M
Funding Rounds
1
Last Funding
2023-06-28

About ExeVir Bio

ExeVir is a clinical stage company focused on developing novel antibody therapies to prevent and treat infectious diseases. Their mission is to address current public health threats like COVID-19 and dengue, and respond to future outbreaks with speed and agility, particularly for vulnerable patients such as the immunocompromised.

Products & Services

Antibody Therapies:Based on a unique modular and multi-specific single domain antibody (VHH) platform, ExeVir is building a pipeline of therapies targeting infectious diseases, with an initial focus on COVID-19 and dengue.

Specialties

Antibody therapy development Infectious disease control Camelid antibody fragment (VHH) technology COVID-19 and dengue treatment

Funding History

Debug: View Raw Funding Data
# Type Amount Fields Date Fields Investors
1 RT: Grant
T: -
FT: Grant 		A: 1600000
MR: -
FA: EUR 1.6 million
FAN: 1600000 		D: 2023-06-28
FD: 2023-06-28 		1 investors
Grant Latest
2023-06-28
$1.6M
1 investor (Pro only)

Growth Metrics

+45%
Employee Growth
YoY
3.2x
Funding Growth
Last Round
12
Markets
Operating
10K+
Customers
Active

View 3 more growth metrics with Pro

Unlock All Metrics
Mock Up

Team & Leadership

X

Xavier Saelens

Group Leader at the VIB-UGent Center for Medical Biotechnology

LinkedIn (Pro only)
N

Nico Callewaert

Science Director

LinkedIn (Pro only)
P

Peter Piot

Scientific advisor

B

Barney Graham

Scientific advisor

C

Camille Nelson Kotton

Scientific advisor

G

Geert Leroux-Roels

Scientific advisor

View 20 more team members with Pro

Unlock Full Team Directory

Recent News

ExeVir Bio Announces New Product Launch

2 days ago

Company unveils innovative solution to transform the industry, expanding market reach and capabilities...

Read more →

Leadership Team Expands with Industry Veteran

1 week ago

New executive brings 20+ years of experience to accelerate growth and strategic initiatives...

Read more →

Company Recognized as Industry Leader

2 weeks ago

Receives prestigious award for innovation and customer satisfaction in competitive market...

Read more →

View 2 more news articles with Pro

Unlock Full News Feed
Mock Up

Key Competitors

C1

Competitor Alpha

Series B · $50M raised

C2

Competitor Beta

Series C · $120M raised

C3

Competitor Gamma

Series A · $25M raised

C4

Competitor Delta

Seed · $10M raised

Mock Up

Company Details

Website
exevir.com
Industries
Biotechnology / Healthcare
Company Size
~460 employees (est.)

Similar Companies

Discover AI-powered company recommendations based on industry, funding, and team profiles.

Upgrade to Pro

Technology Stack

Discover the backend, frontend, and infrastructure technologies powering this company's products.

Upgrade to Pro